Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome)

BACKGROUND: Twenty-eight treatment-naïve mucopolysaccharidosis II patients (16 months–7.5 years) received 0.5 mg/kg idursulfase weekly for one year in NCT00607386. Serum anti-idursulfase immunoglobulin G antibodies (Abs) were seen in 68% of patients. METHODS: This post hoc analysis examined the rela...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Orphanet J Rare Dis
Hlavní autoři: Pano, Arian, Barbier, Ann J, Bielefeld, Bonnie, Whiteman, David AH, Amato, David A
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2015
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4416269/
https://ncbi.nlm.nih.gov/pubmed/25902842
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-015-0265-2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky